BTL Group, a prominent provider of medical solutions, has taken legal action against Lexter Microelectronic Engineering Systems S.L., the manufacturer of the WonderFace device. The lawsuit was filed on October 8, 2025, in the Unified Patent Court, alleging patent infringement related to BTL’s innovative EMFACE® technology. This technology has transformed facial lifting procedures by integrating selective muscle stimulation with radiofrequency heating through hands-free applicators, creating a new category for facial treatments.
The lawsuit aims to halt the distribution of WonderFace devices across multiple countries, highlighting the serious implications of patent enforcement in the medical technology sector. “We will vigorously defend our intellectual property to protect the investments of our clients,” stated Tomas Schwarz, CEO of the BTL Enterprise Group. He emphasized that this legal action is the first step in a broader strategy to challenge any parties that infringe upon BTL’s innovations.
Significance of the Lawsuit
The outcome of this case will have a direct impact across 18 jurisdictions, showcasing the extensive reach of the Unified Patent Court. For BTL, protecting its patents is crucial, given the competitive nature of the medical devices market. The EMFACE® technology is a key part of BTL’s product offerings, which also include items like EXION®, EMSCULPT NEO®, and EMSELLA®. With over 200 patents and a dedicated team of more than 600 engineers, BTL continues to push the boundaries of medical treatments.
The decision to pursue this lawsuit underscores BTL’s commitment to safeguarding its innovations and maintaining its position as a leader in the medical device industry. Legal experts suggest that the ruling could set a precedent for how patent rights are enforced in the rapidly evolving field of medical technology.
In addition to its legal efforts, BTL remains focused on advancing medical solutions across various sectors, including dermatology, plastic surgery, orthopaedics, and rehabilitation. The company’s dedication to innovation is evident in its extensive research and development initiatives.
For further information about BTL’s EMFACE® technology and its other offerings, interested parties can visit www.emface.com.